a549-hace2-tmprss2 cells (InvivoGen)
InvivoGen is a verified supplier 
InvivoGen manufactures this product 
96
Structured Review
InvivoGen
a549-hace2-tmprss2 cells
A549 Hace2 Tmprss2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 5884 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a549+hace2+tmprss2+cells/A549-hACE2-TMPRSS2+Cells/custom%40a549-hace2tpsa%4010%2E64898%2F2026%2E08%2E14%2E744970
Average 96 stars, based on 5884 article reviews
A549 Hace2 Tmprss2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 5884 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a549+hace2+tmprss2+cells/A549-hACE2-TMPRSS2+Cells/custom%40a549-hace2tpsa%4010%2E64898%2F2026%2E08%2E14%2E744970
Average 96 stars, based on 5884 article reviews
a549-hace2-tmprss2 cells - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
In Vitro:Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARSCoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARS-CoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Activity Assay:Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARSCoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025 Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC 50 ]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC , a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025. Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC50]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC (Table A1), a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARS-CoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Enzyme-linked Immunosorbent Assay:Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARSCoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025 Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC 50 ]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC , a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025. Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC50]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC (Table A1), a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in Article Title: Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants Article Snippet: .. To evaluate the in vitro antiviral activity of RDV and ODV against the Omicron variants BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2, XBC.1.6, and XBF, a previously described SARS-CoV-2 anti-nucleoprotein enzyme-linked immunosorbent assay (ELISA) was utilized in Concentration Assay:Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025 Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC 50 ]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC , a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in Article Title: Antiviral Activity of Remdesivir and Obeldesivir Against SARS-CoV-2 Omicron Subvariants That Were Circulating from September 2023 Through June 2025. Article Snippet: .. To evaluate the antiviral activity (half-maximal effective concentration [EC50]) of RDV and ODV against clinical isolates of Omicron subvariants BA.2.86.1, JN.1.7, KP.2, KP.3.1.1, KP.3.3, XBB.2, and XEC (Table A1), a nucleoprotein enzyme-linked immunosorbent assay (ELISA) in |
